Scarica l'app Stockscreener
10.68
0.47%
-0.05
Precedente Chiudi:
$10.73
Aprire:
$10.73
Volume 24 ore:
3.07M
Relative Volume:
1.04
Capitalizzazione di mercato:
$2.39B
Reddito:
$509.86M
Utile/perdita netta:
$165.35M
Rapporto P/E:
15.75
EPS:
0.6779
Flusso di cassa netto:
$107.55M
1 W Prestazione:
+3.09%
1M Prestazione:
+20.00%
6M Prestazione:
-0.56%
1 anno Prestazione:
-26.65%
Intervallo 1D:
$10.61
$10.87
Intervallo di 1 settimana:
$10.03
$10.91
Portata 52W:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
10.68 | 2.39B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-10 | Ripresa | Raymond James | Outperform |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo! Finance Canada
(ADMA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Investors May Respond To ADMA Biologics (ADMA) Peer‑Reviewed Validation Of IVIG Safety And Purity - Yahoo Finance
Could ADMA Biologics' New IVIG Data Be A Catalyst For Investor Interest? - RTTNews
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process - Yahoo Finance
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ADMA Biologics Inc. Stock Grades | ADMA - Barron's
Can ADMA Biologics (NASDAQ:ADMA) Keep Scaling Its Plasma-Derived Pipeline? - Kalkine Media
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - Yahoo Finance
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Zacks Investment Research
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
(ADMA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market - Yahoo Finance
ADMA Biologics (ADMA), Why Is It Back In The Spotlight? - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo! Finance Canada
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today - Yahoo Finance
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Analysis: Potential Upside of 86.61% Sparks Investor Interest - DirectorsTalk Interviews
INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - mykxlg.com
Adma Biologics Stock Price Forecast. Should You Buy ADMA? - StockInvest.us
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
ADMA Biologics IncCommon Stock (Nasdaq:ADMA) Price Chart - The Chronicle-Journal
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech Gem With 84% Upside Potential - DirectorsTalk Interviews
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
ADMAAdma Biologics Inc Volatility & Greeks - Finviz
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 76% Potential Upside - DirectorsTalk Interviews
ADMA: Adma Biologics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Trading Systems Reacting to (ADMA) Volatility - Stock Traders Daily
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A Promising 82% Potential Upside - DirectorsTalk Interviews
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
Class action lawsuit filed against ADMA Biologics for misleading investors and undisclosed transactions - Pluang
Class action lawsuit filed against ADMA Biologics for misleading investors and undisclosed transactions - Pluang
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty - Pluang
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
ADMA Biologics (ADMA) After Strong Q2 Results And Reaffirmed Guidance Is It A Bargain - Sahm
Nomura Small Cap Growth Fund's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
Investigation launched into ADMA Biologics for alleged revenue inflation via channel-stuffing. - Pluang
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking the 79% Potential Upside for Investors - DirectorsTalk Interviews
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum - Sahm
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adma Biologics Inc Azioni (ADMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director |
May 12 '26 |
Buy |
8.01 |
12,500 |
100,125 |
513,884 |
| Grossman Jerrold B | Director |
May 11 '26 |
Buy |
8.01 |
12,500 |
100,125 |
501,384 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Guiheen Lawrence P. | Director |
Mar 13 '26 |
Option Exercise |
3.66 |
30,000 |
109,800 |
135,520 |
| Tade Brad L. | Former Officer |
Mar 10 '26 |
Proposed Sale |
15.81 |
50,026 |
790,911 |
0 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance |
Mar 09 '26 |
Option Exercise |
3.20 |
10,096 |
32,331 |
476,696 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance |
Mar 09 '26 |
Sale |
15.63 |
10,096 |
157,800 |
466,600 |
| Kestenberg-Messina Kaitlin M. | Officer |
Mar 09 '26 |
Proposed Sale |
15.39 |
10,096 |
155,377 |
0 |
| ELMS STEVE | Director |
Mar 06 '26 |
Buy |
15.39 |
7,000 |
107,730 |
2,045,730 |
2.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):